Compare Exelixis Inc. Common Stock (EXEL) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Exelixis Inc. Common Stock vs Hims and Hers Health Inc — how do they compare? Exelixis Inc. Common Stock trades at $59.11 (market cap $14.62B), while Hims and Hers Health Inc trades at $29.12 (market cap $6.55B). The key difference: Exelixis Inc. Common Stock is far larger — about 2.2× Hims and Hers Health Inc's market cap, and Exelixis Inc. Common Stock is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Exelixis Inc. Common Stock for 0 Days and Hims and Hers Health Inc for 21 Days on average.
| EXEL | HIMS | |
|---|---|---|
Market Cap | $14.62B | $6.55B |
Volume | 2,684,957 | 14,842,814 |
Sector | Health | Health |
52-Week High | $59.13 | $62.76 |
52-Week Low | $34.54 | $14.52 |
Typical Hold Time | 0 Days | 21 Days |
Enterprise Value | $13.95B | $7.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.
The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Exelixis Inc. Common Stock
Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
